Aura Biosciences, Inc. (AURA)
Automate Your Wheel Strategy on AURA
With Tiblio's Option Bot, you can configure your own wheel strategy including AURA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AURA
- Rev/Share 0.0
- Book/Share 2.5529
- PB 2.5148
- Debt/Equity 0.1441
- CurrentRatio 11.0595
- ROIC -0.5043
- MktCap 398067747.0
- FreeCF/Share -1.5972
- PFCF -4.9721
- PE -3.3983
- Debt/Assets 0.1187
- DivYield 0
- ROE -0.5863
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AURA | H.C. Wainwright | -- | Buy | -- | $22 | May 28, 2025 |
News
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common …
Read More
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect
Read More
Aura Biosciences to Participate in Upcoming Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
Read More
About Aura Biosciences, Inc. (AURA)
- IPO Date 2021-10-29
- Website https://www.aurabiosciences.com
- Industry Biotechnology
- CEO Dr. Elisabet de los Pinos Ph.D.
- Employees 106